Cargando…

3202 Columbia University’s Personalized IRB Liaison Service: Evaluation over its initial 2.5 years

OBJECTIVES/SPECIFIC AIMS: National concerns about IRB-related research delays have led to re-assessment of IRB review processes at institutional levels. We sought to address whether a dedicated IRB Liaison Service at the Irving Institute’s central location could provide additional useful staff suppo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Green, Nancy, Abedin, Zainab, Teller, Allan, Muhammad, Kawthar, Ruotolo, Brenda, Stiles, Deborah F., Ferreira, Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2019
Materias:	Regulatory Science & Translational Methods
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6799778/ http://dx.doi.org/10.1017/cts.2019.266

Ejemplares similares

4186 Single IRB and the CTSI: Liaison Model for the IRB Reliance Process
por: Caldwell, Christine Sego, et al.
Publicado: (2020)

A personalized Institutional Review Board Liaison Service: Evaluation over its initial 30 months
por: Abedin, Zainab, et al.
Publicado: (2020)

3080 Ensuring Quality in Investigator-Initiated Clinical Trials through Monitoring Concepts Training
por: Spinrad, Amelia, et al.
Publicado: (2019)

Use of SmartIRB Does Not Reduce IRB Review Time in a Non-federally Funded, Multi-Site Malnutrition Study
por: Lamers-Johnson, Erin, et al.
Publicado: (2022)

3076 Findings from the first year of California’s Workplace Violence Prevention in Healthcare standard (Title 8, Section 3342)
por: Odes, Rachel, et al.
Publicado: (2019)

3523 Innovative Approaches to Clinical Research on Placebo Effects: A Regulatory Science Perspective
por: Uweh, Kimberly
Publicado: (2019)

Drug Lag and Key Regulatory Barriers in the Emerging Markets
por: Wileman, Harriet, et al.
Publicado: (2010)

Regulations and guidelines governing stem cell based products: Clinical considerations
por: George, Bobby
Publicado: (2011)

Regulatory Considerations for Biosimilars
por: Nellore, Ranjani
Publicado: (2010)

Registration of Medical Devices
por: George, Bobby
Publicado: (2010)

Implications of ICH-E5: Assessment of drug's sensitivity to ethnic factors and necessity of a bridging study for global drug development
por: Gupta, Sandeep Kumar
Publicado: (2011)

Regulatory requirements for marketing fixed dose combinations
por: Jayasheel, B. G.
Publicado: (2010)

Injury and death in clinical trials and compensation: Rule 122 DAB
por: Ghooi, Ravindra. B.
Publicado: (2013)

Key points of technical review for the registration of SARS-CoV-2 antigen/antibody tests
por: Li, Hongran, et al.
Publicado: (2021)

China NMPA perspective on clinical evaluation of SARS-CoV-2 antibody test reagents in the process of emergency approval
por: Lv, Yunfeng, et al.
Publicado: (2020)

Key points of technical review for the registration of SARS-CoV-2 nucleic acid tests in China
por: Li, Hongran, et al.
Publicado: (2021)

China's NMPA perspective on the clinical performance of SARS-CoV-2 antigen test reagents
por: Lv, Yunfeng, et al.
Publicado: (2022)

IRB Process Improvements: A Machine Learning Analysis
por: Shoenbill, Kimberly, et al.
Publicado: (2017)

How local IRBs view central IRBs in the US
por: Klitzman, Robert
Publicado: (2011)

Advancing a Framework for Regulatory Use of Real-World Evidence: When Real Is Reliable
por: Dreyer, Nancy A.
Publicado: (2018)

4349 Survey of Regulatory Reforms to Address Comprehension of Clinical Trial Results
por: Kirkland, Matthieu, et al.
Publicado: (2020)

392 Basic Researcher Interviews to iDentify Gaps to Enabling Translation (BRIDGE Translation)
por: Thepmankorn, Parisorn, et al.
Publicado: (2023)

Dairis Rihards Irbe
por: Irbe, Dairis Rihards
Publicado: (2023)

The SMART IRB platform: A national resource for IRB review for multisite studies
por: Cobb, Nichelle, et al.
Publicado: (2019)

Performance of IRBs in China: a survey on IRB employees and researchers’ experiences and perceptions
por: Liu, Xing, et al.
Publicado: (2022)

Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model
por: Tonnelier, Arnaud, et al.
Publicado: (2011)

Indian Regulatory Update: Jan-May 2014
por: Suvarnapathaki, Kedar
Publicado: (2014)

Sensory irritation as a basis for setting occupational exposure limits
por: Brüning, Thomas, et al.
Publicado: (2014)

Indian Regulatory Update: June-August 2014
por: Suvarnapathaki, Kedar
Publicado: (2014)

Indian regulatory update 2013
por: Suvarnapathaki, Kedar
Publicado: (2013)

Indian Regulatory Update: September-November 2013
por: Suvarnapathaki, Kedar
Publicado: (2014)

Indian Regulatory Update: January-March 2015
por: Suvarnapathaki, Kedar
Publicado: (2015)

Good Clinical Practice Training: Identifying Key Elements and Strategies for Increasing Training Efficiency
por: Arango, Jaime, et al.
Publicado: (2016)

Translating New Science Into the Drug Review Process: The US FDA’s Division of Applied Regulatory Science
por: Rouse, Rodney, et al.
Publicado: (2017)

Indian Regulatory Update: January-December 2017
por: Bhave, Amita
Publicado: (2018)

Standardisation of defined approaches for skin sensitisation testing to support regulatory use and international adoption: position of the International Cooperation on Alternative Test Methods
por: Casati, S., et al.
Publicado: (2017)

Predicting in vivo effect levels for repeat-dose systemic toxicity using chemical, biological, kinetic and study covariates
por: Truong, Lisa, et al.
Publicado: (2017)

Indian Regulatory Update: January – March 2018
por: Bhave, Amita
Publicado: (2018)

Current pesticide dietary risk assessment in light of comparable animal study NOAELs after chronic and short-termed exposure durations
por: Zarn, Jürg A., et al.
Publicado: (2017)

Indian regulatory update April–October 2018
por: Bhave, Amita, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vtugbn3g0c02choob4t9ob2v77